Why is Puig Brands stock sliding today?

Puig Brands' stock experienced a 3.5% decline, trading at €16.88, following the company's announcement of a €1.2 billion acquisition of Esteve's 50% stake in ISDIN, a dermatology-focused skincare brand. The negative market reaction was primarily due to investors' concerns over the acquisition's financial implications, rather than its strategic value.

The transaction, expected to close by the end of Q1 2027, requires an upfront payment of €900 million, followed by a deferral of €300 million to the first quarter of 2029. This financing is a mix of internal resources and new debt, which analysts anticipate could significantly increase Puig's net leverage ratio in the short term, limiting its financial flexibility when the premium beauty sector faces uncertain consumer demand.

The lack of market support, with U.S. equity benchmarks also declining, and the global risk-off sentiment further exacerbated the situation. Puig's peers in the luxury beauty and fragrance industry, such as L’Oréal, also felt the impact of the cautious sentiment surrounding large-scale M&A deals in the sector. The combination of the ISDIN acquisition's scale, debt-based financing, and a mildly negative macro environment led to Puig's stock hitting its session low as investors weighed the cost of the company's ambition to expand its skincare portfolio against the near-term strain on its financial profile.